These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 9607185)

  • 21. Sequence-specific inhibition of gene expression in intact human skin by epicutaneous application of chimeric antisense oligodeoxynucleotides.
    Wingens M; Pfundt R; van Vlijmen-Willems IM; van Hooijdonk CA; van Erp PE; Schalkwijk J
    Lab Invest; 1999 Nov; 79(11):1415-24. PubMed ID: 10576212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimization of ex vivo pressure mediated delivery of antisense oligodeoxynucleotides to ICAM-1 reduces reperfusion injury in rat cardiac allografts.
    Feeley BT; Poston RS; Park AK; Ennen MP; Hoyt EG; Vriens PW; Robbins RC
    Transplantation; 2000 Mar; 69(6):1067-74. PubMed ID: 10762209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advantages of antisense drugs for the treatment of oral diseases.
    Nedbal W; Teichmann B
    Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):183-91. PubMed ID: 12162701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
    Oberbauer R
    Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oligonucleotide-based gene therapy for cardiovascular disease: are oligonucleotide therapeutics novel cardiovascular drugs?
    Morishita R; Aoki M; Kaneda Y
    Curr Drug Targets; 2000 Jul; 1(1):15-23. PubMed ID: 11475534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antisense oligonucleotides as inhibitors of signal transduction: development from research tools to therapeutic agents.
    Dean NM; McKay R; Miraglia L; Geiger T; Müller M; Fabbro D; Bennett CF
    Biochem Soc Trans; 1996 Aug; 24(3):623-9. PubMed ID: 8878816
    [No Abstract]   [Full Text] [Related]  

  • 27. Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer.
    Gokhale PC; Soldatenkov V; Wang FH; Rahman A; Dritschilo A; Kasid U
    Gene Ther; 1997 Dec; 4(12):1289-99. PubMed ID: 9472552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic potential of oligonucleotide-based therapy in cardiovascular disease.
    Morishita R; Kaneda Y; Ogihara T
    BioDrugs; 2003; 17(6):383-9. PubMed ID: 14614761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.
    Hussain M; Shchepinov M; Sohail M; Benter IF; Hollins AJ; Southern EM; Akhtar S
    J Control Release; 2004 Sep; 99(1):139-55. PubMed ID: 15342187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of the intercellular adhesion molecule-1(ICAM-1) in endotoxin-induced pneumonia evaluated using ICAM-1 antisense oligonucleotides, anti-ICAM-1 monoclonal antibodies, and ICAM-1 mutant mice.
    Kumasaka T; Quinlan WM; Doyle NA; Condon TP; Sligh J; Takei F; Beaudet Al; Bennett CF; Doerschuk CM
    J Clin Invest; 1996 May; 97(10):2362-9. PubMed ID: 8636417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antisense therapy in oncology: new hope for an old idea?
    Tamm I; Dörken B; Hartmann G
    Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
    Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS
    Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells.
    Aukunuru JV; Ayalasomayajula SP; Kompella UB
    J Pharm Pharmacol; 2003 Sep; 55(9):1199-206. PubMed ID: 14604462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice.
    Geiger T; Müller M; Dean NM; Fabbro D
    Anticancer Drug Des; 1998 Jan; 13(1):35-45. PubMed ID: 9474241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene therapy with transcription factor decoy oligonucleotides as a potential treatment for cardiovascular diseases.
    Tomita N; Azuma H; Kaneda Y; Ogihara T; Morishita R
    Curr Drug Targets; 2003 May; 4(4):339-46. PubMed ID: 12699354
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antisense candidates against protein kinase C-alpha designed based on phylogenesis and simulant structure of mRNA.
    Song HF; Tang ZM; Yuan SJ; Zhu BZ; Liu XW
    Acta Pharmacol Sin; 2003 Mar; 24(3):269-76. PubMed ID: 12617778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antisense oligonucleotide Elk-1 suppresses the tumorigenicity of human hepatocellular carcinoma cells.
    Ying TH; Hsieh YH; Hsieh YS; Liu JY
    Cell Biol Int; 2008 Feb; 32(2):210-6. PubMed ID: 17950002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo transfection of NF-kappaB decoy oligodeoxynucleotides attenuate renal ischemia/reperfusion injury in rats.
    Cao CC; Ding XQ; Ou ZL; Liu CF; Li P; Wang L; Zhu CF
    Kidney Int; 2004 Mar; 65(3):834-45. PubMed ID: 14871403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Propynylated phosphodiester oligonucleotides inhibit ICAM-1 expression in A549 cells on electroporation.
    Meunier L; Monsigny M; Roche AC
    Antisense Nucleic Acid Drug Dev; 2001 Apr; 11(2):117-23. PubMed ID: 11334140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of secondary structure prediction in antisense drug design targeting protein kinase C-alpha mRNA and QSAR analysis.
    Song HF; Tang ZM; Yuan SJ; Zhu BZ
    Acta Pharmacol Sin; 2000 Jan; 21(1):80-6. PubMed ID: 11263253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.